Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Medtronic
Moodys
Johnson and Johnson
Farmers Insurance
McKesson
Federal Trade Commission
Daiichi Sankyo
Julphar

Generated: December 15, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 203441

« Back to Dashboard

NDA 203441 describes GATTEX KIT, which is a drug marketed by Nps Pharms Inc and is included in one NDA. It is available from one supplier. There are twenty-one patents protecting this drug and one Paragraph IV challenge. Additional details are available on the GATTEX KIT profile page.

The generic ingredient in GATTEX KIT is teduglutide recombinant. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the teduglutide recombinant profile page.
Summary for 203441
Tradename:GATTEX KIT
Applicant:Nps Pharms Inc
Ingredient:teduglutide recombinant
Patents:21
Formulation / Manufacturing:see details
Generic Entry Opportunity Date for 203441
Generic Entry Date for 203441*:
Constraining patent/regulatory exclusivity:
Dosage:
POWDER;SUBCUTANEOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 203441
Suppliers and Packaging for NDA: 203441
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
GATTEX KIT teduglutide recombinant POWDER;SUBCUTANEOUS 203441 NDA Shire-NPS Pharmaceuticals, Inc. 68875-0101 68875-0101-2 30 VIAL in 1 CARTON (68875-0101-2) > .5 mL in 1 VIAL (68875-0101-1)
GATTEX KIT teduglutide recombinant POWDER;SUBCUTANEOUS 203441 NDA Shire-NPS Pharmaceuticals, Inc. 68875-0102 68875-0102-1 1 KIT in 1 CARTON (68875-0102-1) * .5 mL in 1 SYRINGE, PLASTIC * .7 mL in 1 PACKET * .5 mL in 1 VIAL (68875-0101-1)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:POWDER;SUBCUTANEOUSStrength5MG/VIAL
Approval Date:Dec 21, 2012TE:RLD:Yes
Regulatory Exclusivity Expiration:Dec 21, 2019
Regulatory Exclusivity Use:TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME (SBS) WHO ARE DEPENDENT ON PARENTERAL SUPPORT
Patent:➤ Try a Free TrialPatent Expiration:Apr 14, 2020Product Flag?YSubstance Flag?YDelist Request?
Patented Use:TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME WHO ARE DEPENDENT ON PARENTERAL SUPPORT
Patent:➤ Try a Free TrialPatent Expiration:Sep 18, 2022Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME WHO ARE DEPENDENT ON PARENTERAL SUPPORT

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Cantor Fitzgerald
Cipla
Teva
McKinsey
QuintilesIMS
Boehringer Ingelheim
Citi
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.